Tirzepatide is administered as a once-weekly subcutaneous injection, starting at 2.5 mg for 4 weeks (an initiation dose), then typically increasing to 5 mg, with possible further increases to 7.5, 10, 12.5, or 15 mg based on clinical response and tolerability
Adlyxin was a once-daily subcutaneous injectable prescription medicine that was approved for type 2 diabetes
There is no way to painlessly cover that population through any combination of employer-sponsored insurance, Medicaid, and Medicare without hikes in premiums, co-pays and (for government programs) tax hikes or more deficit spending
At this concentration, 1 unit = 0.01 mL 25 mcg on a U100 insulin syringe
What are the side effects and safety precautions